At Turner Pope Investments, we are committed to proving quality research to our Corporate Clients which is MiFID II compliant and disseminated to our database of Retail, Professional, Family Offices and Institutions.
Turner Pope Investments takes a holistic view to service provision and our research plays a central and vital part within it. Although the investment world is rapidly changing (as for example, the influence of social media), this further enhances the need for widely distributable quality research. We provide marketing communications, which are pertinent to the widest possible audience, on a regular basis, keeping companies ‘on the radar’ and front of mind with investors across the board.
We have specialist Oil & Gas and Mining Analysts and can provide relevant coverage across various other sectors.
Please be aware that any research displayed on this page is posted one month in arrears. If you would like to benefit from these insightful reports as they are distributed to our clients, please click below and complete the contact form so we can add you to our research distribution list.
Avacta is planning to submit an IND/CTA application in early 2020 to test the TMAC™ linker in a Phase I study in patients with selected tumours. The IND (Investigational New Drug) submission relates to the US application process while the CTA (Clinical Trial Application) applies to the European market. This is good news for the company as Avacta is in a position to test this critical TMAC linker in humans early in 2020, well ahead of its original plans.
Labskin AI has entered into testing agreements with three exciting new clients. In aggregate, these contracts are worth approximately £290,000 with the value of all contract revenue expected to fall into the current year. In order to accommodate these agreements and anticipated new business, the company is also increasing its Labskin laboratory capacity by 50%. We believe that this latest news validates both Integumen’s strategy to focus on larger contracts from Labskin AI services and also the company’s expertise in Cannabidiol (CBD) based product testing.
Midatech is focused on the research and development (R&D) of medicines for rare cancers. Through its portfolio of three proprietary drug delivery technology platforms, in tandem with a highly specialised team of scientists located in the UK and Spain, the company is developing novel drug delivery solutions to improve existing therapies and develop new treatments for a range of lethal diseases. Midatech focuses on making existing medicines better, using its proprietary technologies.
Integumen is a vertically integrated business focused on the group’s core Labskin AI technology platform. Collaborations with a wide range of partners in the pharmaceutical and cosmetic products sectors, among many others, enable Labskin’s clients to test consumer products on acne, eczema, psoriasis and dandruff populated skin under real-world conditions, viewing the results in real-time.
Tower is in the final stages of planning the NJOM3 appraisal well on the Njonjifield (Tower: 100%), located offshore Cameroon. NJOM3 is planned to be drilled to a total depth of 1,100m, probing at least three reservoirs zones identified by the NJOM1B and NJOM2 discovery wells. NJOM3 is designed to confirm the reservoir thickness on the Njonji field, supplement existing well data and evaluate additional formations that could provide valuable resource upside.
Oil production from the VG-4 well at the West Brentwood field in California (Reabold 50%) has commenced at an initially constrained rate as a consequence of significant volumes of associated gas. However, a tie-in to the local gas pipeline is underway and when completed, daily volumes of both oil and gas can be increased significantly providing a significant increase in revenue to the company.
Coro’s strategy to become a mid-tier South East Asian focused E&P company has accelerated with the news that the company has completed the cash and shares payments amounting to a total consideration of US$4.8m to acquire a 15% interest in the Duyung PSC offshore Indonesia. Additional to this, Coro has also provided a further US$10.5 contribution to the operator’s 2019 drilling campaign on the licence.
Avacta’s interim results demonstrate that the company is making solid progress with its in-house therapeutic programmes and first-in-man clinical data for its Affimer therapeutic platform is expected in late 2020. This is underpinned by the company’s recent commercial agreements with LG Chem Life Sciences and Tufts University Medical School, among several others, which have the potential to deliver long term revenue growth to the company.
Catenae Innovation is a provider of digital media and technology focused on Distributed Ledger Technology or ‘blockchain’ solutions. The company has developed a portfolio of products and services which have the potential to provide innovative solutions and commercial advantage to Catenae’s growing client base.
W Resources has announced that the jig and mill for its flagship La Parrilla tungsten-tin project are on schedule for mechanical completion in the current
month and the majority of equipment for the company’s new concentrator is now on site. With completion of these key phases of development imminent and
most other infrastructure work complete, we expect that the company will be able to ramp-up production significantly in Q2 2019.